Company Overview

Company Overview

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

Genovis was founded in 1999 by Sarah Fredriksson and the business initially focused on nanoparticles (NIMT®) intended for both the preclinical and clinical markets. Beginning around 2010, the company launched advanced unique enzymes for analysis of biological drugs, and antibodies particularly for therapeutic use. The enzyme portfolio grew and more enzymes in various formats have been added since then. In 2015 Genovis streamlined its operations to specialize in development, production and sales of enzymes for the growing global pharmaceutical industry that works on developing biologicals for the future.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.

  • Svenska